Arabic Arabic English English French French German German
dark

Novartis’ Kymriah Disappoints in Phase III for Aggressive B-Cell NHL

Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Built-In Financial Services Can Help Healthcare Providers Rebound Post-Pandemic

Next Post

Happify Health & Higi Partnership to Create an AI-Driven Patient-Engagement Ecosystem that Makes Value-Based Healthcare Accessible Worldwide

Related Posts
Total
0
Share